絞り込み

16758

広告

福島第一原発 首都圏から社員移動させず 感染拡大防止へ対策 (NHK)

新型コロナウイルスの感染が全国的に拡大し緊急事態宣言が東京都などに出される中、東京電力・福島第一原子力発電所では、感染が広がって廃炉作業が滞らないよう、原則とし...

  1. 厚生科学審議会 (予防接種・ワクチン分科...
  2. スパコン「富岳」を治療薬開発に活用…「最...
  3. 第23回厚生科学審議会予防接種・ワクチン...
  4. 令和2年度厚生労働省補正予算案の概要

ニュース一覧

Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge.

著者 Leong P , Macdonald MI , Ko BS , Bardin PG
Med J Aust.2019 Mar 25 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Medical

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist but combined disease is often not recognised. Since symptoms overlap significantly, it is common for patients' presentations to be attributed to one disease alone, and for the other to be overlooked. The effect of COPD and CVD goes beyond the shared risk factors of smoking and advancing age. The presence of COPD adversely affects cardiac disease and vice versa. In comparison to individuals with one disease alone, those with both conditions have a higher mortality rate, experience more frequent exacerbations with more hospitalisations and have worse quality of life. More patients with mild and moderate COPD die from CVD than from COPD, and there is a higher rate of arrhythmias, particularly atrial fibrillation. Accurate and timely diagnosis is therefore crucial. Retrospective evidence indicates that individuals with COPD and CVD may have better outcomes with appropriate CVD pharmacotherapy, yet robust prospective evidence is lacking. Inhaled medications for patients with stable COPD improve quality of life and reduce exacerbations, but there is limited evidence that they reduce mortality. A low threshold for investigation and treatment of CVD in COPD and COPD in CVD is essential.
PMID: 30907000 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード